Co-Diagnostics, Inc. to Host Booth at CARPHA Conference
June 11 2018 - 5:30AM
Business Wire
Co-Diagnostics, Inc. (NASDAQ: CODX), (“Co-Diagnostics” or
the “Company”), a molecular diagnostics company with a unique,
proprietary platform for the development of molecular diagnostic
tests, announced today that they will be hosting a booth at the
63rd Annual 2018 Caribbean Public Health Agency (CARPHA) Health
Research Conference in St. Kitts & Nevis on June 14-16.
Co-Diagnostics, Inc. CEO Dwight Egan remarked, “We are excited
to be attending this important event following the recent
advancement in our CoPrimers™ platform technology in multiplex
tests for SNP detection and the announcement of our CoPrimer
technology being used in a research project conducted by the Wang
Group at Stanford University. This event is an excellent
opportunity to network with researchers and health professionals
that attend from across the Caribbean Region, Latin America, North
America and Europe.”
The Company has several key laboratory placements in the region
and views this conference as a powerful forum for Co-Diagnostics to
communicate the benefits of the Company’s infectious disease
molecular tests, and the heightened specificity of the Company’s
CoPrimer platform which enables robust multiplexing within a single
reaction. Co-Diagnostics’ proprietary platform also has broad
applications for agriculture and liquid biopsy for early cancer
detection.
Mr. Egan continued, “We believe our marketing efforts in the
Caribbean and Central American regions are making significant
inroads and setting the stage for substantive, material revenue as
the Company’s products are released as fully approved diagnostics.
We anticipate being able to release news on those fronts in the
very near future, and that our prospects will look even brighter as
we continue to build on our current momentum."
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular
diagnostics company with a proprietary diagnostic testing
technology and development platform that intends to manufacture and
sell reagents used for diagnostic tests that function via the
detection and/or analysis of nucleic acid molecules (DNA or RNA),
and license the use of its platform to other non-competing
developers.
Forward-Looking Statements:
This press release contains forward-looking statements.
Forward-looking statements can be identified by words such as
"believes," "expects," "estimates," "intends," "may," "plans,"
“feel,” "will" and similar expressions, or the negative of these
words. Such forward-looking statements are based on facts and
conditions as they exist at the time such statements are made and
predictions as to future facts and conditions. Readers of
this press release are cautioned not to place undue reliance on any
forward-looking statements. The Company does not undertake
any obligation to update any forward-looking statement relating to
matters discussed in this press release, except as may be required
by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180611005387/en/
Company Contact:Co-Diagnostics, Inc.Andrew
BensonCo-Diagnostics Investor
Relations801-438-1036investors@codiagnostics.comorInvestor
Contact:Lytham Partners, LLCJoe Diaz, Robert Blum and Joe
Dorame602-889-9700codx@lythampartners.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Oct 2023 to Oct 2024